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The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor and member of the basic
helix-loop-helix-PAS family. AHR is activated by numerous dietary and endogenous compounds that
contribute to its regulation of genes in diverse signaling pathways including xenobiotic metabolism,
vascular development, immune responses and cell cycle control. However, it is most widely studied for
its role in mediating 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) toxicity. The AHR target gene and
mono-ADP-ribosyltransferase, TCDD-inducible poly-ADP-ribose polymerase (TIPARP), was recently
shown to be part of a novel negative feedback loop regulating AHR activity through mono-ADP-
ribosylation. However, the molecular characterization of how AHR regulates TIPARP remains elusive.
Here we show that activated AHR is recruited to the TIPARP promoter, through its binding to two genomic
regions that each contain multiple AHR response elements (AHREs), AHR regulates the expression of
both TIPARP but also TIPARP-AS1, a long non-coding RNA (lncRNA) which lies upstream of TIPARP exon 1
and is expressed in the opposite orientation. Reporter gene and deletion studies showed that the distal
AHRE cluster predominantly regulated TIPARP expression while the proximal cluster regulated TIPARP-
AS1. Moreover, time course and promoter activity assays suggest that TIPARP and TIPARP-AS1 work in
concert to regulate AHR signaling. Collectively, these data show an added level of complexity in the AHR
signaling cascade which involves lncRNAs, whose functions remain poorly understood.
© 2017 Published by Elsevier Inc.1. Introduction
The aryl hydrocarbon receptor (AHR) is a basic helix-loop-helix/
period-ARNT-single-minded ligand-activated transcription factor
essential in mediating the adaptive responses to xenobiotics. It is
activated by the environmental contaminant, 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) but also by numerous other
endogenous and dietary compounds [1]. Ligand binding initiates
the nuclear translocation of cytosolic AHRwhere it heterodimerizes
with the aryl hydrocarbon receptor nuclear translocator (ARNT).
The heterodimer binds to aryl hydrocarbon response elements
(AHREs; 50-TnGCGTC-30) locatedwithin the regulatory regions of its
targeted genes, including cytochrome P450 1A1 (CYP1A1), AHR
repressor (AHRR) and TCDD-inducible poly-ADP-ribose polymerase
(TIPARP; also known as, PARP7/ARTD14) [2,3]. Binding of the AHR/nstitute of Basic Medical Sci-
slo, Norway.
J. Matthews).ARNT complex to the DNA leads to recruitment of co-regulatory
proteins resulting in modulation of gene expression. Although the
AHR is essential in mediating the toxicity of TCDD and structurally-
related compounds [4], it also plays a critical role in development
and in the maintenance of tissue homeostasis [5]. Moreover, AHR
regulates immune functions, inflammation, stem differentiation
and plays a role in cancer [6]. Because of its wide physiological and
pathophysiological roles, AHR has emerged as an important phar-
macological target [7].
TIPARP is one of many TCDD-induced target genes that are part
of the AHR dependent transactivation cascade, sometimes referred
to as the AHR gene battery [8]. It is a member of the poly-adenosine
diphosphate (ADP)-ribose polymerase (PARP) family. PARPs use
nicotinamide adenine dinucleotide (NADþ) as a substrate to
transfer one molecule of ADP-ribose, mono-ADP-ribosylation, or
several ADP-ribose moieties, poly-ADP-ribosylation, to specific
amino acid residues on themselves and/or on target proteins [9].
TIPARP mono-ADP-ribosylates itself and other proteins, including
histones and AHR [3,10]. Although TIPARP's exact cellular role re-
mains unknown, it has been reported to regulate pluripotency of
G. Grimaldi et al. / Biochemical and Biophysical Research Communications 495 (2018) 2356e2362 2357embryonic stem cells, cellular responses to viral infection and is a
downstream target of platelet derived growth factor receptor
activation [11e13]. We recently reported that Tiparp/ mice
exhibit increased AHR responsiveness and increased sensitivity to
dioxin-induced toxicity and wasting syndrome, confirming that
TIPARP is a repressor of AHR activity [10].
Long noncoding RNAs (lncRNAs) are a class of transcribed, but
not translated, RNA molecules greater than 200 bp. They are poorly
conserved and their molecular mechanisms and functions are still
not fully understood [14]. However, they have been shown to be
implicated in a wide range of processes and operate via different
mechanisms. They regulate the recruitment of transcriptional
regulatory complexes to chromatin, RNA maturation and transport,
and protein synthesis [15,16].
AHR regulates various noncoding RNAs, which play roles in
AHR-dependent signaling pathways. In zebrafish, AHR2 (the
orthologue of mammalian AHR) strongly upregulates the lncRNA,
slincR, which silences the adjacently located sox9b gene by acting as
an RNA macromolecule. SlincR is essential for development as
reduced expression leads to altered neurological responses [17].
Chronic cigarette smoke exposure regulates pulmonary and miR-
NAs by activating AHR [18], while fine particulate matter (PM2.5)
may illicit its toxicological response by activating a series of
lncRNAs via AHR [19]. Taken together this data highlight additional
players in gene regulation via the AHR pathway.
Both mouse and human express a long non-coding RNA, which
lies upstream of exon 1 and is expressed in the opposite orientation
compared to TIPARP mRNA, referred to as TIPARP antisense RNA 1
(TIPARP-AS1). In mouse, this lncRNA is known to be induced by Ahr
in response to xenobiotics [20]. A genome-wide study in HeLa cells
placed TIPARP-AS1 as an early response gene following oxidative
stress. However, whether TIPARP-AS1 contributes to the regulation
of TIPARP expression or whether it is involved in AHR signaling
remains unknown [20].
Here we characterize the regulation of TIPARP and investigate
the regulation of the lncRNA, TIPARP-AS1, by AHR. Overall our
findings show that AHR directly regulates both TIPARP mRNA but
also TIPARP-AS1 revealing an additional complexity in the AHR-
TIPARP signaling axis.
2. Materials and methods
2.1. Chemicals
TCDD was purchased from Wellington Laboratories (Guelph,
ON, Canada). Dimethyl sulfoxide (DMSO), cell culture media, fetal
bovine serum (FBS) and trypsin were purchased from Sigma-
Aldrich (St. Louis, MO, USA). All other reagents were of the high-
est quality available from commercial vendors.
2.2. Plasmids
The regulatory region of human TIPARP spanning 4.2 kb and
various truncations of this regionwere PCR amplified from genomic
DNA fromMCF-7 cells. The amplicons were then digestedwith BglII
and KpnI and then ligated into BglII and KpnI sites of the pGL3 Basic
vector (Promega, Madison,WI, USA) or in the case of AHRE cluster I,
AHR cluster II and AHRE cluster II R.C. in pGL3 promoter vector
(Promega, Madison, WI, USA). The TIPARP-AS1 overexpression
vector was created by PCR amplifying a partial TIPARP-AS1
sequence from commercial human genomic DNA (Roche, Basel
Switzerland). The product was digested with MscI and KpnI and
then ligated into the Kpn1 and internal MscI site in the pGL3 TIPARP
4.2 kb vector. The complete TIPARP-AS1 sequence was excised with
KpnI and HindIII and subcloned into the similarly digestedpCDNA3.1(þ) vector (Thermo Fisher Scientific, Waltham, MA, USA).
Primer sequences are available upon request.2.3. Cell culture
MCF-7 human breast carcinoma cells and HuH7 human hepa-
toma cells were purchased from ATCC (Manassas, VA, USA). MCF-7
AHRko cells were obtained by ZFN-mediated AHR gene knockout
and described elsewhere [21]. All cells were cultured in low-
glucose Dulbecco's Modified Eagle's Media (DMEM; glucose 1 g/L)
supplemented with 10% FBS and 1% (w/v) penicillin/streptomycin
(P/S). They were maintained at 37 C with 5% CO2 and sub-cultured
every 2e3 days or when cells reached 80% confluency.2.4. Chromatin immunoprecipitation
MCF-7 and MCF-7 AHRko cells were plated in a 10 cm culture
dish, after 24 h the media was changed to DMEM low glucose
phenol red free mediawith 5% (v/v) dextran/coated charcoal (DCC)-
stripped FBS and 1% P/S. After 48 h they were treated with 10 nM
TCDD for the indicated time. ChIP assays were done as previously
described [22] using 1 mg of anti-AHR (H-211) (Santa Cruz
Biotechnology, Santa Cruz, CA) or anti-ARNT (H-172) (Santa Cruz).
Isolated DNA was quantified by qPCR using SsoFast EvaGreen SYBR
Supermix (Biorad, Hercules, CA).2.5. Transient transfection and reported gene assay
MCF-7 and MCF-7 AHRko were transfected with 500 ng of the
reporter gene constructs containing truncations of TIPARP regula-
tory region or the empty vector. Cells were also transfected with
100 or 400 ng pRC CMV2 AHR and 100 or 400 ng ARNT-FLAG-
pcDNA4B or 700 or 800 ng pcDNA. HuH7 cells were transfected
with the indicated amounts of pEGFP1-C2-TiPARP and/or
pCDNA3.1-TPAS-1 or pCDNA3.1 as well as 200 ng pGudLuc, a
CYP1A1-regulated gene activity vector (kindly provide by Michael
Denison University of California Davis). All cell lines were trans-
fected with 100 ng pEGFP-C2 and 200 ng pCH110-b-Gal or 100 ng
pRenilla-SV40 to normalize for transfection efficiency. Trans-
fections were done using Lipofectamine LTX or Lipofectamine 2000
(Thermo Fisher Scientific, Waltham, MA). After 8 h of transfection
cells were treated with DMSO or 10 nM TCDD for 16 h before
measuring activity with Luciferase Assay System or the Dual-
Luciferase Reporter Assay System (Promega, Madison, WI).2.6. RNA isolation and qPCR
Cells were seeded in 6-well plates 24 h prior to treatment with
10 nM TCDD for the indicated time. RNA was isolated with Aurum
Total RNA Mini Kit (Biorad) following the manufacturer's instruc-
tion. RNA was reverse transcribed using either SuperScript III
(Invitrogen) or High-Capacity cDNA Reverse Transcription Kit
(Thermo Scientific). Transcripts levels were quantified by qPCR
using SsoFast EvaGreen SYBR supermix (Biorad). All primers se-
quences are available upon request.2.7. Statistics
All data are expressed as mean± standard error of the mean
(SEM). A One-way Analysis of Variance (ANOVA) with Tukey's
multiple comparisons test or Student's t-test were used to deter-
mine statistical significance (p< .05) using GraphPad Prism 5 and
Microsoft Excel.
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3.1. Ligand-induced AHR recruitment to the TIPARP promoter
The human TIPARP gene, located on chromosome 3, is composed
of 6 exons, exons 2e5 code for the full-length protein with a mo-
lecular weight of 76 kDa. Previous genome wide ChIP-chip and
ChIP-sequencing studies identified the ligand-dependentFig. 1. TIPARP promoter has two clusters of AHREs to which AHR binds. A. Schematic repres
Recruitment of AHR to the two AHRE clusters on the TIPARP promoter. Recruitment levels sig
Activation of the AHR pathway and upregulation of TIPARP and CYP1A1. Cells were treated
denotes greatly significant (p< .05) changes in gene expression upon TCDD treatment. D.
TIPARP regulatory region or the empty vector. Cells were then treated with TCDD for 18 h. A
S.E.M.recruitment of AHR to two unique sites upstream of the TIPARP
gene [23,24]. Transcription factor binding site analysis of two AHR
bound regions using Genomatix (http://www.genomatix.de/),
identified 4 AHREs in one AHR bound sequence and 2 in the other,
which we refer to as AHRE cluster I and cluster II, respectively
(Fig. 1A).
TCDD-induced recruitment of AHR to each cluster was
confirmed using ChIP-qPCR (Fig. 1B). Here we used the well-entation of the human TIPARP promoter. MCF-7 cells were treated with 10 nM TCDD B.
nificantly greater (p< .05) than untreated cells are denoted with a lowercase letter a. C.
for 18 h with TCDD. Gene expression levels were normalized to DMSO treated cells, a
MCF-7 cells were transfected with reporter gene constructs containing truncations of
ll the data shown are the mean of three experiments and the error bars represent the
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AHR and ARNT and is routinely used to study AHR signaling [22].
Cells were treated for 0.5 h with 10 nM TCDD and recruitment of
AHR and ARNT to AHRE cluster I and cluster II was determined.
Significant enrichment of AHR and ARNT to both regions was
observed (Fig. 1B). A higher percentage of AHR binding occurred at
cluster I compared with cluster II, suggesting an increased number
of AHRmolecules at that region. As previously reported, expression
levels of TIPARP and CYP1A1, a marker of AHR pathway activation,
increased following TCDD treatment (Fig. 1C).
To determine which AHREs contributed to TIPARP regulation
various luciferase vectors containing all or fragments of a 4.2 kb
upstream regulatory region were made. The constructs were
transfected into MCF-7 cells treated with DMSO or 10 nM TCDD for








































































Fig. 2. AHRE cluster I is also regulated by transcription factors other than AHR. MCF-7 AH
regulatory region or the empty vector and treated for 18 h with 10 nM TCDD. A. All truncation
bearing only cluster II. B. MCF-7 AHRko cells were also transfected with increasing concentrat
increase of reported gene activity upon TCDD treatment compared to DMSO treatment, de
represent the S.E.M.included the full length 4.2 kb promoter, a 2.7 kb, and a 1.1 kb
truncated region and just the AHRE cluster I, showed high levels of
constitutive reporter gene activity. Despite the recruitment of AHR
to cluster II, the two truncations containing cluster II failed to
exhibit any TCDD-dependent increases in reporter gene activity
(Fig. 1D). This suggested that cluster I was important in regulating
TIPARP expression even though TCDD failed to enhance luciferase
activity in any of the constructs tested. To further investigate the
AHR and TCDD-dependent regulation of TIPARP and to exclude the
possibility that the high constitutive activity of TIPARP promoter
fragments containing cluster I was not due to AHR activation by
ligands in the cell culture medium [25], we tested the TIPARP pro-
moter deletions in MCF-7 AHRko cells [21]. The transfected TIPARP
promoter constructs containing cluster I also showed high consti-









50 100 1500 200






AHR and ARNT (ng)
2.7 kbLuc
a









































Rko cells transfected with reporter gene constructs containing truncations of TIPARP
s containing cluster I show elevated basal activity. There is no activity on the constructs
ions of AHR and ARNT. Overexpression of AHR and ARNT showed a significant (p< .05)
noted by a. All the data shown are the mean of three experiments and the error bars
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increases in luciferase activity were observedwith TIPARP promoter
constructs containing cluster II. Transfection of 4.2 kb, 2.7 kb, and
1.1 kb construct in MCF-7 AHRko cells with increasing amounts of
AHR and ARNT and treated with TCDD resulted in a significant
TCDD-dependent increase in luciferase assay (Fig. 2BeE).
The lack of TCDD-dependent increases in reporter gene activity
from TIPARP promoter deletion that only contained cluster II was
intriguing and suggested that either AHR recruitment to the region
was nonproductive or that binding of AHR to cluster II regulates
another gene. The AHRE cluster II is located 35 bp upstream of
TIPARP-AS1 expressed on the negative strand (Fig. 1A). TIPARP-AS1
encodes a 2556 bp linear lncRNA of unknown function that over-
laps with the untranslated exon 1 of TIPARP. To test if AHR regulates
TIPARP-AS1, we cloned the TIPARP-AS1 (TPAS) promoter, which
included the1517 to2059 region relative toTIPARP start site. The
reverse complement of cluster II (cluster II RC) was also cloned into
a luciferase vector to test if this region acted as an enhancer to
regulate TIPARP-AS1 expression. The TIPARP-AS1 promoter and the
cluster II RC exhibited higher level of constitutive activity compared
with 1.8 kb region containing cluster II. TCDD treatment caused a
small, but significant, increase in cluster II RC-mediated luciferase
activity. No TCDD-dependent increases were observed for TIPARP-
AS1 promoter (Fig. 3A). High constitutive activity of the TIPARP
promoter and cluster II R.C. vectors was also observed in trans-
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Fig. 3. AHRE cluster II regulates TIPARP-AS1 rather than TIPARP. MCF-7 (A) and MCF-7 AHR
regulatory region containing cluster II and cloned in the reverse complement or the empty
cloned in the reverse complement there is high basal gene reporter activity, suggesting that
shows significant (p< .05) increase of reported gene activity upon TCDD treatment compar
reverse complement showed elevated basal activity. Overexpression of AHR and ARNT sh
compared with DMSO treatment, denoted a. All the data shown is the mean of three expeincrease in cluster II R.C.-mediated luciferase activity was only
observed after overexpression of AHR and ARNT in MCF-7 AHRko
cells (Fig. 3B). However, overexpression of AHR and ARNT failed to
increase TPAS promoter driven luciferase activity in the presence of
TCDD. Taken together these results suggest that AHR binding to
cluster II regulates TIPARP-AS1 rather than TIPARPmRNA expression
levels.3.2. Temporal mRNA expression
To determine the effect of AHR activation in regulating both
TIPARP mRNA and TIPARP-AS1 levels we did a time course expres-
sion analysis in TCDD-treated MCF-7 cells. A significant increase in
the TIPARP-AS1 expression was observed 45min (Fig. 4A). Peak
expression of TIPARP-AS1 preceded that of TIPARP, which occurred
after 1.5 h before declining. CYP1A1 levels were still increasing at
the end of the time-course (3 h) as expected. No increases were
observed in TCDD treated MCF-7 AHRko cells (Fig. 4B).
To test the role of TIPARP-AS1 in TIPARP-dependent repression of
AHR signaling, we did CYP1A1-regulated reporter gene studies in
HuH7 human hepatoma cells. In agreement with previous studies
[3], increasing concentrations of TIPARP reduced TCDD-dependent
increases in luciferase activity (Fig. 4C). Overexpression of TIPARP-
AS1 had no effect on TCDD-induced reporter gene activity (Fig. 4D).
However, overexpression of TIPARP-AS1 improved the ability of
TIPARP to repress CYP1A1-regulated luciferase activity (Fig. 4E).c
b
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vector and treated for 18 h with 10 nM TCDD. A. In MCF-7 cells when AHRE cluster II is
AHRE cluster II regulates TIPARP-AS1. The vector containing only the AHRE cluster II also
ed with DMSO. B. Transfection of MCF-7 AHRko cells with AHRE cluster II cloned in the
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Fig. 4. TIPARP and TIPAR- AS1work in concert to regulate AHR signaling. A.MCF-7 cells were treated for 18 h with 10 nM TCDD. TIPARP-AS1 gene expression (left panel) peaks earlier
than TIPARP (middle panel) following dioxin treatment. Gene expression levels were normalized to DMSO treated cells, a denotes greatly significant (p< .05) changes in gene
expression upon TCDD treatment. B. MCF-7 AHRko cells were treated for 18 h with 10 nM TCDD. A lack of AHR results in no upregulation of TIPARP-AS1 (right panel), TIPARP (middle
panel) or CYP1A1 (right panel). C. Huh7 cells were transfected with pGudLuc, a CYP1A1-regulated luciferase activity vector and increasing concentrations of pGFP-TIPARP and/or
TIPARP-AS1 overexpression plasmids or pEGFP. Cells were then treated with TCDD for 18 h. Increasing amounts of TIPARP reduced luciferase activity (left panel). Overexpression of
TIPARP-AS1 enhanced TIPARP-dependent repression of reporter gene activity. Significant decrease (p< .05) in luciferase activity in cells transfected with pGFP-TIPARP or pGFP-
TIPARP-AS1 compared to those transfected with pEGFP are denoted a. b indicates a significant decrease (p< .05) in luciferase activity in cells transfected with both with pGFP-
TIPARP or TIPARP-AS1 compared to those transfected with pGFP-TIPARP alone. All the data shown are the mean of three experiments and the error bars represent the S.E.M.
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regulate AHR signaling.4. Discussion
Previous work by our group has shown that TIPARP negatively
regulates AHR through a novels negative feedback loop, where
increased levels of TIPARP repress AHR activity in a process that
requires TIPARP catalytic activity [3]. We also showed that loss of
Tiparp expression in mice increases their sensitivity to TCDD-
dependent toxicity [10]. Here we show that AHR binds to the
TIPARP promoter region where it drives the expression of TIPARP
mRNA levels, but also the lncRNA, TIPARP-AS1.
Characterization of the upstream regulatory region of the TIPARP
promoter revealed two clusters of AHR response elements, with the
more distal (cluster I) showing strong recruitment of AHR after
TCDD exposure. AHRE cluster II is located downstream of the un-
translated exon of Tiparp (which overlaps the lncRNA) and ispositioned between TIPARP AS-1 and TIPARP. Reporter gene assays
showed that the AHRE cluster I drives basal levels of TIPARP
expression but this is not enhanced by dioxin treatment, AHRE
cluster II did not show any basal or treatment induced expression of
the reporter gene when cloned in the same orientation as TIPARP.
However, when cloned in the reverse complement orientation it
showed significantly greater reporter activity. The presence of basal
reporter activity also in MCF-7 AHRko cells indicates that there are
other transcription factors involved in this regulation. AHR is
required for the TCDD-dependent increase of both TIPARP and its
cis-antisense RNA since, no changes were observed in treated AHRko
cells. This is also conserved in the mouse, where Ahr binding to an
AHRE cluster positioned in the first intron of the Tiparp gene and
upstream of the Tiparp-as1 (4931440P22Rik) modulates expression
of both the protein-coding mRNA and the lncRNA [20]. It is esti-
mated that approximately 40% of the mouse and human transcripts
form complex loci with cis-antisense transcript pairs, with the
majority involving ncRNAs [26]. Our study provides another
G. Grimaldi et al. / Biochemical and Biophysical Research Communications 495 (2018) 2356e23622362example of the impact of lncRNA on gene regulation and tran-
scription factor function.
We show that TIPARP-AS1 peak expression precedes that of
TIPARP in response to dioxin. This suggests a regulatory role for the
cis-antisense lncRNA, TIPARP-AS1 in regulating transcription of the
TIPARP mRNA. In support of this, we found that overexpression of
TIPARP-AS1 enhanced TIPARP's ability to regulate genes such as
CYP1A1 suggesting that the lncRNA plays an important role in
regulating TIPARP-mediated AHR signaling. Although the molecu-
lar mechanism of this cooperation and the precise function of
TIPARP-AS1 still remain elusive. Further studies investigating how
other pathways regulate TIPARP-AS1 and whether the two types of
RNA always form a transcriptional unit will help dissect the over-
lapping and independent mechanisms through which TIPARP
operates.
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